Proactive Investors
20 Jul 2026, 12:44 UTC · 15h ago
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
20 Jul 2026, 12:44 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
OKYO Pharma plans to begin the Phase 3 NEPTUNE pivotal trial for urcosimod in the second half of 2026. — The transition to a Phase 3 trial is a critical value-inflection point for clinical-stage biotech companies as it is the final step before potential regulatory approval.
+0.60The FDA provided positive feedback during a Type D meeting, suggesting a single-trial approval pathway may be possible for urcosimod. — A potential single-trial approval pathway significantly reduces the time and cost to market, increasing the probability of commercial success.
+0.50OKYO Pharma reported cash and cash equivalents of approximately $20.6 million as of March 31, 2026. — Positive liquidity reduces immediate dilution risk and provides the necessary runway to execute the planned Phase 3 trial.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company successfully raised $25 million, filed its annual report showing progress, and received positive FDA feedback for its Phase 3 trial pathway.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
11h ago
